Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.

Atherosclerosis. Supplements - 1 May 2015

Gouni-Berthold Ioanna, Berthold Heiner K

Abstract excerpt

Familial hypercholesterolemia (FH) is a disease associated with very high plasma concentrations of low-density lipoprotein cholesterol (LDL-C) and premature cardiovascular disease. It is difficult in these high risk patients, exposed lifelong to very high LDL-C, to reach target LDL-C concentrations, which require >50% LDL-C reduction, even when on maximally tolerated statin therapy and on apheresis if available....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticholesteremic Agents
Share to Apolipoprotein B-100
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carrier Proteins

Share to Cholesterol, LDL

Share to Hyperlipoproteinemia Type II

Share to Oligonucleotides

Share to Receptors, LDL

Source

Identifiers

PMID: 25936301
DOI: 10.1016/j.atherosclerosissup.2015.02.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.PMID 25936301Read ↗

Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemiaSemantic proximity Read ↗

Novel treatments for familial hypercholesterolemia: pharmacogenetics at work.Semantic proximity Read ↗

Lomitapide for the treatment of hypercholesterolemia.Semantic proximity Read ↗

Balancing Low-density Lipoprotein Cholesterol Reduction and Hepatotoxicity With Lomitapide Mesylate and Mipomersen in Patients With Homozygous Familial Hypercholesterolemia.Semantic proximity Read ↗

Lomitapide for the management of homozygous familial hypercholesterolemia.Semantic proximity Read ↗

Familial hypercholesterolaemia.Semantic proximity Read ↗

My Approach to the Patient With Familial Hypercholesterolemia.Semantic proximity Read ↗

Microsomal transfer protein (MTP) inhibition-a novel approach to the treatment of homozygous hypercholesterolemia.Semantic proximity Read ↗

Familial hypercholesterolemia.Semantic proximity Read ↗

Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With HypercholesterolemiaSemantic proximity Read ↗

MTP Gene Variants and Response to Lomitapide in Patients with Homozygous Familial Hypercholesterolemia.Semantic proximity Read ↗

Use of microsomal triglyceride transfer protein inhibitors in patients with homozygous familial hypercholesterolemia: translating clinical trial experience into clinical practice.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.